Edition:
United Kingdom

People: Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

17.28USD
9:00pm BST
Change (% chg)

$-0.32 (-1.82%)
Prev Close
$17.60
Open
$17.31
Day's High
$17.35
Day's Low
$17.00
Volume
1,048,399
Avg. Vol
1,550,589
52-wk High
$23.33
52-wk Low
$2.36

Granowitz, Craig 

Dr. Craig B. Granowitz, M.D., Ph.D. is Chief Medical Officer of the Company. Dr. Granowitz has a strong leadership background in medical affairs, with extensive experience managing a multi-national medical affairs organization for a portfolio of leading cardiovascular products. Prior to joining Amarin, Dr. Granowitz was senior vice president and head of global medical affairs, global human health at Merck, where he developed and implemented an entirely new global medical affairs organization following Merck's merger with Schering-Plough. In this capacity, among his numerous achievements, he provided critical medical affairs support in the run-up to and read-out of Merck's cardiovascular outcomes study, IMPROVE-IT. From 2003 to 2008, he was group vice president, head of global medical affairs for Schering-Plough. His work at Schering-Plough and, later, Merck, was critical to the growth and success of a global medical affairs organization that spans multiple therapeutic areas and now operates in more than 80 countries worldwide. Prior to joining Schering-Plough, Dr. Granowitz co-founded Proliance Pharmaceuticals, a venture-capital backed pharmaceutical development and finance management start-up company.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

--

John Thero

2,769,490

Michael Kalb

--

Stephen Ketchum

1,198,590

Joseph Kennedy

1,201,640

Aaron Berg

--
As Of  31 Dec 2014